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BACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-
generation inhibitor of vascular endothelial growth factor receptors, combined with platinum doublets in patients with advanced
non-small cell lung cancer (NSCLC) and other solid tumours.
METHODS: In all, 49 patients received axitinib 5mg twice daily (b.i.d.) with paclitaxel/carboplatin or gemcitabine/cisplatin in 3-week
cycles. Following determination of the maximum tolerated dose, a squamous cell NSCLC expansion cohort was enroled and
received axitinib 5mg b.i.d. with paclitaxel/carboplatin.
RESULTS: Two patients experienced dose-limiting toxicities: febrile neutropenia (n¼ 1) in the paclitaxel/carboplatin cohort and fatigue
(n¼ 1) in the gemcitabine/cisplatin cohort. Common nonhaematologic treatment-related adverse events were hypertension (36.7%),
diarrhoea (34.7%) and fatigue (28.6%). No gradeX3 haemoptysis occurred among 12 patients with squamous cell NSCLC. The
objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n¼ 27) and 23.8% for patients receiving
axitinib/gemcitabine/cisplatin (n¼ 21). Pharmacokinetics of axitinib and chemotherapeutic agents were similar when administered
alone or in combination.
CONCLUSION: Axitinib 5mg b.i.d. may be combined with standard paclitaxel/carboplatin or gemcitabine/cisplatin regimens without
evidence of overt drug–drug interactions. Both combinations demonstrated clinical efficacy and were well tolerated.
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New therapeutic strategies are needed to improve the efficacy of
chemotherapy regimens for advanced solid tumours. For patients
with advanced non-small cell lung cancer (NSCLC), platinum-
based doublets remain a standard of care (Stinchcombe and
Socinski, 2009). However, these treatments result in only modest
improvements in survival (Burris, 2009). Addition of targeted
agents, which act on specific signalling pathways involved in
tumour progression, to chemotherapy regimens may improve
clinical outcomes.
The vascular endothelial growth factor (VEGF) pathway has a
key role in tumour-related angiogenesis, and its deregulation is
characteristic of many solid tumours (Brown et al, 1993; Ikeda
et al, 1999; Berns et al, 2003; Saad et al, 2004; Keedy and Sandler,
2007). Novel agents have been developed to target the VEGF ligand
or its receptor. In several phase III studies, inhibition of VEGF
signalling by the anti-VEGF antibody bevacizumab in combination
with chemotherapy improved patient outcomes compared with
chemotherapy alone (Hurwitz et al, 2004; Sandler et al, 2006;
Miller et al, 2007; Reck et al, 2010). In patients with advanced non-
squamous NSCLC, bevacizumab prolonged overall survival (OS)
when combined with paclitaxel and carboplatin compared with
chemotherapy alone (median OS, 12.3 vs 10.3 months) (Sandler
et al, 2006), and prolonged progression-free survival, but not OS,
when combined with gemcitabine and cisplatin (Reck et al, 2010).
Investigation of antiangiogenic agents with different mechanisms
of action, such as tyrosine kinase inhibition, in combination with
chemotherapy is warranted. Results from a phase III study showed
that adding sorafenib, an inhibitor of multiple tyrosine kinases, to
carboplatin/paclitaxel did not prolong OS compared with
chemotherapy alone in patients with NSCLC (Scagliotti et al,
2010). Nevertheless, other tyrosine kinase inhibitors that selec-
tively inhibit VEGF receptors may still offer clinical benefit when
added to chemotherapy.
Axitinib is an oral, potent and selective second-generation
tyrosine kinase inhibitor of VEGF receptors 1, 2 and 3 (Hu-Lowe
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et al, 2008). When combined with docetaxel, carboplatin or
gemcitabine in human tumour models, axitinib enhanced the
antitumour efficacy of these agents (Hu-Lowe et al, 2008). In phase
II studies of several tumour types, axitinib showed single-agent
activity and was well tolerated (Rixe et al, 2007; Cohen et al, 2008;
Rini et al, 2009; Schiller et al, 2009). In a phase II study of patients
with advanced NSCLC receiving single-agent axitinib, median OS
was 14.8 months (Schiller et al, 2009), which compares favourably
with chemotherapy (Burris, 2009). These data suggest axitinib may
enhance the efficacy of standard chemotherapy regimens for the
treatment of selected solid tumours, including NSCLC.
Here, we report safety, efficacy and pharmacokinetic findings
from a phase I study of combination treatment with axitinib plus
paclitaxel/carboplatin or gemcitabine/cisplatin in patients with
advanced solid tumours, including squamous cell NSCLC.
PATIENTS AND METHODS
Study design and end points
This was a phase I, open-label, multicentre, dose-finding study
consisting of nine treatment cohorts, plus an expansion cohort of
patients with squamous cell NSCLC who were enroled after
determination of the maximum tolerated dose (MTD) of axitinib
plus paclitaxel/carboplatin. Here, we report findings from cohorts
that received axitinib in combination with either paclitaxel/
carboplatin (cohorts 1, 2 and 3 plus expansion) or gemcitabine/
cisplatin. Findings from other treatment cohorts are presented in
an accompanying article (Martin et al, 2012). Primary end point
was MTD of axitinib combined with either paclitaxel/carboplatin
or gemcitabine/cisplatin. Secondary end points included safety,
tumour response rates and plasma pharmacokinetic profiles.
This study was performed in accordance with the study protocol
approved at each participating centre, International Conference on
Harmonisation Guidelines on Good Clinical Practice and applic-
able local regulatory requirements and laws. All patients provided
written informed consent. This trial is registered on Clinical-
Trials.gov (NCT00454649).
Patients
Patients aged X18 years with any histologically or cytologically
proven advanced solid malignancy suitable for treatment with
paclitaxel/carboplatin or gemcitabine/cisplatin were eligible. Inclu-
sion criteria for all cohorts included an Eastern Cooperative
Oncology Group performance status (ECOG PS) of 0 or 1; no pre-
existing uncontrolled hypertension (antihypertensive medications
were permitted); adequate organ function; and no prior
chemotherapy with platinum salts or taxanes for metastatic disease
except as noted below; adjuvant treatment with platinum salts or
taxanes must have been completedX12 months before enrolment.
For patients receiving gemcitabine/cisplatin, any type of previous
chemotherapy was allowed and, for patients in the expansion
cohort, any type of previous treatment was allowed. Patients with
NSCLC with squamous cell histology, or mixed histology that was
predominantly squamous, were eligible for the expansion cohort,
which received axitinib plus paclitaxel/carboplatin.
Exclusion criteria included myocardial infarction, congestive
heart failure, cerebrovascular accident (including transient ischaemic
attack) or pulmonary embolus o12 months before enrolment;
haemoptysis (40.5 teaspoon blood per day) within 1 week of
enrolment; and at least one lung lesion with cavitation or any
lesion invading and/or supporting large blood vessels.
Study treatments
Treatment schedules are shown in Figure 1. All patients received
axitinib twice daily (b.i.d.) with food. In vitro studies indicate
axitinib noncompetitively inhibits the cytochrome P450 (CYP) 2C8
enzyme (unpublished data) involved in paclitaxel metabolism
(Monsarrat et al, 1993; Steed and Sawyer, 2007). Owing to potential
for drug–drug interactions between axitinib and paclitaxel, the
axitinib lead-in dose was administered at 1, 3 and 5mg b.i.d. for
sequential cohorts 1, 2 and 3, respectively, started 3–5 days before
the first dose of chemotherapy and continued for 2 days after the
first chemotherapy dose. Cohorts 1, 2 and 3 were to enrol three to
six patients, depending on the number of patients that experienced
a dose-limiting toxicity (DLT) during the first cycle (Table 1). If
none of the first three patients experienced a DLT during the first
cycle, the lead-in dose of axitinib was escalated in the subsequent
cohort. If one of the three patients experienced a DLT during the
first cycle, the cohort was expanded to include a total of six
patients, and if one of six patients experienced a DLT during the
first cycle, the lead-in dose of axitinib was escalated in the next
cohort. The lead-in dose of axitinib for the gemcitabine/cisplatin
cohort was 5mg b.i.d. After the lead-in period, axitinib 5mg b.i.d.
was administered continuously in all cohorts. Axitinib was
interrupted 3 days before cycle 2 day 1 of chemotherapy
administration and dosing was resumed on cycle 2 day 3; for
cohorts 1 and 2, starting with cycle 2, axitinib was interrupted 1
day before chemotherapy infusion (day 21) and resumed on day 3
of each subsequent cycle. For the expansion cohort, axitinib was
Cohorts 1–3 (paclitaxel/carboplatin) cycles (3 weeks)
–5, –4
Lead-in
CTChemotherapya
Chemotherapy
Axitinib:
Axitinib
Cohorts 1 and 2
Cohort 3
PK sampling
PK sampling
Gemcitabine/cisplatin cycles (3 weeks)
CT CT
1 3 18 20 1 3 20 201 3Days or –3
C1 C2 C3
–5, –4
1 3 8 18 201 3 20 201 3 88Days or –3
C1 C2 C3
Lead-in
Gem/
Cis
Gem/
Cis
Gem Gem Gem/
Cis
Gem
Figure 1 Treatment schedule for (A) paclitaxel/carboplatin cohorts and
(B) gemcitabine/cisplatin cohort. aChemotherapy (CT)¼ paclitaxel/carbo-
platin for cohort 1, 2 and 3. C¼ cycle; Cis¼ cisplatin; Gem¼ gemcitabine;
PK¼ pharmacokinetic.
Table 1 Axitinib dose escalation in patients receiving paclitaxel/
carboplatin
Cohort
Lead-in dose of
axitinib (b.i.d.)
Patients
enroled (n)
Dose-limiting
toxicities
1 1mga 3 None
2 3mga 5 None
3 5mg 20b Febrile neutropenia
(n¼ 1)
Abbreviation: b.i.d.¼ twice daily. aLead-in dose of axitinib was started 3–5 days
before the first dose of chemotherapy and continued for 2 days after the first
chemotherapy dose (from day –5, –4 or –3 through cycle 1 day 2). bIncludes patients
enroled in the expansion cohort.
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administered at the MTD defined in cohorts 1–3, beginning cycle 1
day 1. All patients continued treatment with axitinib until disease
progression or unacceptable toxicity. After cycle 1, patients with
no grade 42 adverse events (AEs) related to axitinib for
consecutive 2-week periods could have their axitinib dose titrated
to 7mg b.i.d. and then to a maximum of 10mg b.i.d., unless BP
measured 4150/100mmHg or the patient was receiving anti-
hypertensive medication. The axitinib dose was reduced to 3mg
b.i.d., and then to 2mg b.i.d. in patients with grade X3
nonhaematologic treatment-related AEs. For patients who devel-
oped systolic BP 4150mmHg or diastolic BP 4100mmHg, new
or additional antihypertensive therapy was started or the dose of
existing medication increased. If patients developed haemoptysis
(40.5 teaspoon of bright red blood per day), axitinib was
discontinued and a radiologic assessment was to be considered.
For patients in the squamous cell NSCLC expansion cohort who
developed cavitation after enrolment, axitinib was withheld and
patients were assessed on a case-by-case basis. Patients who
permanently discontinued axitinib because of toxicity could
continue to receive chemotherapy as long as treatment was
considered clinically beneficial.
Patients in cohorts 1–3 and the expansion cohort received
paclitaxel (200mgm–2; 3-h infusion) followed by carboplatin (area
under the plasma concentration–time curve (AUC) target of
6mgminml 1; 30-min infusion) every 3 weeks. Patients in the
gemcitabine/cisplatin cohort received cisplatin (80mgm 2 on day 1)
and gemcitabine (1250mgm 2 on days 1 and 8; 30-min infusion),
followed by a 1-week rest period, in 3-week cycles. Chemotherapy
regimens were modified on an individual basis according to
patient tolerability at the discretion of the investigator. Paclitaxel/
carboplatin was delayed in patients with absolute granulocyte
counts o1500 cellsmm 3or platelet counts o100 000 cellsmm 3
and discontinued if recovery did not occur after 4 weeks.
Paclitaxel/carboplatin was withheld in patients with grade X3
haematologic or nonhaematologic toxicities and resumed at one
lower dose level when the toxicity was grade p1. Paclitaxel was
reduced in patients with grade 2 neurotoxicity or withheld until
neurotoxicity was grade p1. The gemcitabine/cisplatin dose was
reduced to 75% in patients with febrile neutropenia, grade 4
neutropenia for X7 days, grade 4 thrombocytopenia, bleeding
grade42 with grade 3 thrombocytopenia or grade 3 nonhaema-
tologic toxicities during the prior cycle. The gemcitabine/cisplatin
dose was reduced to 50% or delayed in patients with grade 4
nonhaematologic toxicities during the prior cycle. Gemcitabine/
cisplatin was delayed by 1 week if the absolute neutrophil count
was o1.0 109 l 1 and/or the platelet count was o100 109 l 1.
If on day 8, the absolute neutrophil count waso1.0 109 l 1 and/or
the platelet count was o100 109 l 1, gemcitabine was not
administered. Cisplatin was discontinued in patients with grade
X2 peripheral neurotoxicity, tinnitus or hearing loss during the
prior cycle. Prophylactic use of colony-stimulating factors was
permitted in patients who experienced infection or grade 4
neutropenia during the previous cycle. Patients who discontinued
chemotherapy because of toxicity or because they completed the
maximum number of cycles according to institutional practice
could continue to receive axitinib as a single agent.
Assessments
The MTD for axitinib plus paclitaxel/carboplatin or gemcitabine/
cisplatin was defined as the dose level at which no more than one
of the first six patients enroled in each cohort experienced a DLT
during the first cycle of therapy, with two or more of the six
patients experiencing a DLT at the next highest dose level. If the
MTD was not exceeded within the planned dose levels, MTD was
defined as the maximum dose tested. Dose-limiting toxicities were
defined as grade 4 neutropenia or thrombocytopenia for X14
days, or grade 4 febrile neutropenia; proteinuria X2 g/24 h;
haemoptysis (X 0.5 teaspoon per day) for X7 days; uncontrolled
grade X3 nonhaematologic toxicity for X7 days; or inability to
resume study treatment within 14 days after stopping because of
axitinib-related toxicity.
Safety was monitored throughout the study, and AE severity was
graded according to the Common Terminology Criteria for
Adverse Events, version 3.0 (Trotti et al, 2003). Physical
examinations, assessment of ECOG PS, chest X-rays and laboratory
tests were conducted at baseline, day 1 of each cycle and at follow-
up (28 days after the last dose). Additional physical examinations
and haematology tests were performed at days 8 and 15 of each
cycle. For the squamous cell NSCLC expansion cohort, chest
X-rays were performed to assess tumour cavitation on even-
numbered cycles when other tumour assessments were not
performed. BP was monitored at each clinic visit, and patients
were issued a home BP monitoring device and diary and asked to
record their BP at least twice daily before each axitinib dose.
Patients were instructed to contact their physicians for systolic
BP4150mmHg or diastolic BP4100mmHg. Home BP measure-
ments were not used for DLT assessments. Tumours were
radiologically assessed every two cycles, according to Response
Evaluation Criteria in Solid Tumours (RECIST version 1.0)
(Therasse et al, 2000).
Pharmacokinetic analysis
The pharmacokinetics of steady-state axitinib alone and che-
motherapy alone, as well as the combination of steady-state
axitinib plus chemotherapy, were evaluated in each patient in all
cohorts except the expansion cohort. Pharmacokinetics of steady-
state axitinib when administered alone were determined using
blood samples collected pre-dose and 1, 2, 3, 4, 6 and 8 h after
dosing on cycle 1 day –1. Pharmacokinetics of chemotherapy when
administered alone were determined using blood samples collected
on cycle 2 day 1. Pharmacokinetics of the combination of steady-
state axitinib and chemotherapy were determined using blood
samples collected on cycle 1 day 1. Samples for paclitaxel/
carboplatin analysis were collected pre-dose and 1, 2, 3, 3.25, 3.5,
4, 5, 6, 8, 24 and 30 h after the start of paclitaxel infusion. Samples
for gemcitabine analysis were collected pre-dose and 0.25, 0.5, 0.75,
1, 1.25, 1.5, 2, 3 and 4 h after the start of infusion in tubes
containing tetrahydrouridine, which prevented continued meta-
bolism of gemcitabine during the processing of samples. Samples
for cisplatin analysis were collected pre-dose and 0.5, 1, 1.5, 2.5,
3.5, 5.5 and 7.5 h after the start of infusion.
Plasma concentrations of axitinib were measured using a
validated high-performance liquid chromatography with tandem
mass spectrometric detection method (LC/MS/MS) (Charles River
Discovery and Development Services; Shrewsbury, MA, USA)
(Rugo et al, 2005). Concentrations of paclitaxel, gemcitabine and
the gemcitabine metabolite 20,20-difluorodeoxyuridine (dFdU) in
sodium heparin plasma were measured using a validated LC/MS/
MS assay (Covance Bioanalytical Services; Indianapolis, IN, USA)
with ranges of 10–2000 ngml–1, 50–50 000 ngml–1 and
500–50 000 ngml–1 for paclitaxel, gemcitabine and dFdU, respec-
tively. Concentrations of platinum from carboplatin and cisplatin
in sodium heparin plasma and plasma ultrafiltrate (PUF) were
measured using a validated inductively coupled plasma-MS assay
(Covance Laboratories; Madison, WI, USA) with ranges of
2.0–1000 ngml–1and 1.0–500 ngml–1 in plasma and PUF, respec-
tively. All pharmacokinetic analyses were conducted using
WinNonlin Professional (version 4.01, Pharsight Corp.; Mountain
View, CA, USA).
Statistical analysis
All patients receiving at least one dose of study medication were
included in the safety analysis. Patients having one or more target
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lesion according to RECIST and a baseline assessment of disease
and who received at least one dose of study medication were
included in the analysis of best objective response. Data were
summarised using means, medians, s.d. and ranges for continuous
data and frequencies and percentages for categorical data.
RESULTS
Patient demographics and disposition
In all, 49 patients were enroled, including 28 patients in the
paclitaxel/carboplatin cohorts and 21 patients in the gemcitabine/
cisplatin cohort (Table 2). The most common tumour type was
NSCLC in 17 patients (34.7%), all of whom were in the paclitaxel/
carboplatin cohorts.
Study treatment duration for individual patients is shown in
Figure 2. Patients received axitinib for a median of 174 days (range
10–656) and 89 days (range 5–992) in the paclitaxel/carboplatin
and gemcitabine/cisplatin cohorts, respectively. The median daily
axitinib dose was 9.8mg (range 4.7–15.1) in patients receiving
paclitaxel/carboplatin and 9.0mg (range 6.0–10.0) in patients
receiving gemcitabine/cisplatin. Dosing of axitinib was reduced in
16 patients (35.7% and 28.6% of patients in the paclitaxel/
carboplatin and gemcitabine/cisplatin cohorts, respectively) and
was interrupted in 24 patients (35.7% and 66.7% of patients in the
paclitaxel/carboplatin and gemcitabine/cisplatin cohorts, respec-
tively). Median number of paclitaxel/carboplatin cycles was 6, 5
and 4 (range 1–6) for cohorts 1, 2 and 3, respectively; median
number of chemotherapy cycles was 4 (range 1–29) and 3 (range
1–9) for gemcitabine and cisplatin, respectively. A total of 26
patients receiving axitinib plus paclitaxel/carboplatin discontinued
the study, including 14 patients because of insufficient clinical
response, 4 patients because of AEs and 8 patients for other
reasons. In the gemcitabine/cisplatin cohort, 20 patients discon-
tinued, including 10 because of insufficient clinical response, 6
because of AEs and 4 for other reasons.
DLTs and MTD
One of the first six patients in cohort 3 receiving axitinib/
paclitaxel/carboplatin experienced a DLT of febrile neutropenia
during the first cycle (Table 1), and the MTD was determined to be
axitinib 5mg b.i.d. continuously in combination with paclitaxel
200mgm–2 and carboplatin (AUC 6mgminml–1). One of the first
six patients receiving axitinib/gemcitabine/cisplatin experienced a
DLT of fatigue during the first cycle; the MTD was determined to
be axitinib 5mg b.i.d. continuously in combination with cisplatin
80mgm–2 (day 1) and gemcitabine 1250mgm–2 (days 1 and 8).
Dose titration to 10mg b.i.d. was achieved in three patients
receiving paclitaxel/carboplatin.
Safety and tolerability
Six patients discontinued the study because of treatment-related
AEs, which were fatigue, cerebrovascular accident and haemopty-
sis (n¼ 1 each) in the paclitaxel/carboplatin cohorts and
hypertension (n¼ 2) and cerebrovascular accident (n¼ 1) in the
gemcitabine/cisplatin cohort. Common treatment-related nonhae-
matologic AEs were hypertension (n¼ 18; 36.7%), diarrhoea
(n¼ 17; 34.7%) and fatigue (n¼ 14; 28.6%) (Table 3). Common
grade X3 treatment-related nonhaematologic AEs across both
treatment arms were fatigue (n¼ 5; 10.2%) and hypertension
(n¼ 5; 10.2%). In addition to the patient in cohort 3 receiving
axitinib/paclitaxel/carboplatin who had a DLT of febrile neutro-
penia during the first cycle, one patient in cohort 2 experienced
grade 4 febrile neutropenia; chemotherapy was reduced in this
patient. In the paclitaxel/carboplatin cohorts, two patients (7.1%)
developed treatment-related stomatitis; both cases were classified
Table 2 Patient baseline characteristics
Axitinib þ
Paclitaxel/
carboplatin,
n¼ 28
Gemcitabine/
cisplatin,
n¼ 21
Male/female, n 21/7 9/12
Age, median (range), years 60 (37–75) 52 (40–79)
ECOG PS 0/1, n 16/12 9/12
Primary tumour type, n (%)
NSCLC 17 (60.7) 0
Melanoma 4 (14.3) 0
Ovarian 3 (10.7) 1 (4.8)
Pancreatic 0 4 (19.0)
Breast 0 3 (14.3)
Head and neck 1 (3.6) 1 (4.8)
Cholangiocarcinoma 0 2 (9.5)
CRC 0 2 (9.5)
Other 3 (10.7)a 8 (38.1)b
Prior therapy, n (%)
Surgery 14 (50.0) 20 (95.2)
Radiotherapy 5 (17.9) 9 (42.9)
Drug therapyc 8 (28.6) 15 (71.4)
Abbreviations: CRC¼ colorectal cancer; ECOG PS¼ Eastern Cooperative Oncology
Group performance status; NSCLC¼ non-small cell lung cancer. aRenal cell
carcinoma, unknown primary tumour (n¼ 2). bBladder, cervical, ectopic hormone
secretion syndrome associated with neoplasia, gastrointestinal, prostate, sarcoma,
small intestine, unknown primary tumour. cIncludes cytotoxic chemotherapy and
targeted agents.
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Figure 2 Duration of study treatment.
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as grade 2. No cases of gradeX3 haemoptysis or grade 5 treatment-
related AEs were reported.
Haematologic laboratory abnormalities occurred in most
patients (Table 3). With the exceptions of lymphopenia in the
gemcitabine/cisplatin cohort and neutropenia in both cohorts, the
majority of abnormalities were grade p2. Grade 3/4 treatment-
related abnormalities reported as AEs were thrombocytopenia
(n¼ 4; 8.2%), neutropenia (n¼ 2; 4.1%) and anaemia and
leukopenia (n¼ 1 each; 2.0%).
Clinical activity
Of the evaluable patients, 15 (31.3%) achieved an objective
response (Table 4), including 3 complete responses (6.3%). An
additional 16 patients (33.3%) had stable disease for 48 weeks.
Objective responses were observed in patients with NSCLC (n¼ 5),
ovarian cancer (n¼ 3), melanoma (n¼ 2) and other tumour types
(n¼ 5).
Pharmacokinetic results
Plasma pharmacokinetic parameters (maximum plasma concen-
tration, AUC, clearance and volume of distribution) for paclitaxel,
carboplatin, gemcitabine and its metabolite dFdU and cisplatin
were similar in the absence or presence of axitinib (Table 5;
Figure 3). Axitinib pharmacokinetic parameters were similar in the
absence or presence of co-administered paclitaxel/carboplatin or
gemcitabine/cisplatin (Table 5; Figure 3).
DISCUSSION
Combination treatment with chemotherapy and an agent targeting
the VEGF pathway has been shown to improve clinical outcome for
several tumour types compared with chemotherapy alone (Hurwitz
et al, 2004; Sandler et al, 2006; Miller et al, 2007; Reck et al, 2010).
In this study, axitinib combined with paclitaxel/carboplatin or
gemcitabine/cisplatin was well tolerated and demonstrated clinical
Table 3 Safety and tolerability findings
(A) Treatment-related nonhaematologic AEs,a n (%)
Axitinib þ
Total, N¼49
Paclitaxel/carboplatin, n¼28 Gemcitabine/cisplatin, n¼ 21
All grades All grades Grade 3/4b All grades Grade 3/4b
Hypertension 18 (36.7) 10 (35.7) 1 (3.6) 8 (38.1) 4 (19.1)
Diarrhoea 17 (34.7) 11 (39.3) 1 (3.6) 6 (28.6) 1 (4.8)
Fatigue 14 (28.6) 9 (32.1) 4 (14.3) 5 (23.8) 1 (4.8)
Proteinuria 10 (20.4) 7 (25.0) 1 (3.6) 3 (14.3) 0
Hand–foot syndrome 9 (18.4) 8 (28.6) 1 (3.6) 1 (4.8) 1 (4.8)
Epistaxis 8 (16.3) 5 (17.9) 0 3 (14.3) 0
Nausea 8 (16.3) 0 0 8 (38.1) 0
Decreased appetite 7 (14.3) 3 (10.7) 0 4 (19.1) 0
Headache 7 (14.3) 1 (3.6) 0 6 (28.6) 1 (4.8)
Rash 7 (14.3) 5 (17.9) 1 (3.6) 2 (9.5) 1 (4.8)
Dysphonia 7 (14.3) 4 (14.3) 0 3 (14.3) 0
Dysgeusia 6 (12.2) 4 (14.3) 0 2 (9.5) 0
Dizziness 5 (10.2) 4 (14.3) 0 1 (4.8) 0
(B) Haematologic laboratory abnormalities, n (%)
Axitinibþ
Total, N¼ 48
Paclitaxel/carboplatin, n¼ 27 Gemcitabine/cisplatin, n¼ 21
All grades All grades Grade 3/4b All grades Grade 3/4b
Anaemia 48 (100) 27 (100) 0 (0) 21 (100) 2 (9.5)
Neutropenia 46 (95.8) 26 (96.3) 25 (92.6) 20 (95.2) 13 (61.9)
Leukopenia 46 (95.8) 26 (96.3) 10 (37.0) 20 (95.2) 10 (47.6)
Thrombocytopenia 43 (89.6) 25 (92.6) 7 (25.9) 18 (85.7) 10 (47.6)
Lymphopenia 40 (83.3) 19 (70.4) 5 (18.5) 21 (100) 14 (66.7)
Abbreviation: AE¼ adverse event. aReported inX10% of patients. bNo grade 5 AEs were reported.
Table 4 Best response to therapy, by RECISTa
n (%)
Axitinibþ
Paclitaxel/carboplatin,
n¼ 27
Gemcitabine/cisplatin,
n¼ 21
Objective response rateb 10 (37.0) 5 (23.8)
Complete response 2 (7.4) 1 (4.8)
Partial response 8 (29.6) 4 (19.0)
Stable disease 11 (40.7) 5 (23.8)
Disease progression 3 (11.1) 3 (14.3)
Indeterminate/missing 3 (11.1) 8 (38.1)
Abbreviation: RECIST¼Response Evaluation Criteria in Solid Tumours. aIncludes
treated patients with at least one target lesion according to RECIST and a baseline
assessment of disease. bComplete responsesþ partial responses.
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efficacy without any overt pharmacokinetic interactions for
various advanced solid tumours. The MTD for axitinib in
combination with paclitaxel/carboplatin or gemcitabine/cisplatin
was 5mg b.i.d.; however, further dose escalation of axitinib was
achieved in some patients tolerating 5mg b.i.d.
Most AEs reported in this study were of mild-to-moderate
grade, and the most common treatment-related nonhaematologic,
grade X3 AEs (hypertension, diarrhoea and fatigue) were
anticipated, based on results from prior phase II studies of
axitinib (Rixe et al, 2007; Cohen et al, 2008; Spano et al, 2008; Rini
et al, 2009; Schiller et al, 2009). Unlike DLTs observed with other
VEGF receptor tyrosine kinase inhibitors, for example, sorafenib,
where skin toxicities such as rash and hand–foot syndrome were
predominant (Moore et al, 2005; Strumberg et al, 2005), DLTs
associated with axitinib in combination with paclitaxel/carboplatin
or gemcitabine/cisplatin were febrile neutropenia and fatigue.
Potential overlapping toxicities between axitinib and the
chemotherapeutic agents, such as fatigue, nausea, diarrhoea and
stomatitis, did not appear to be appreciably exacerbated.
Patients receiving anti-VEGF therapies have an increased risk of
developing hypertension (Jain and Townsend, 2007; Zhu et al,
2007; Wu et al, 2008), and the incidence of hypertension in this
study was consistent with previous axitinib trials (Rixe et al, 2007;
Cohen et al, 2008; Rini et al, 2009; Schiller et al, 2009). Moreover,
grade X3 hypertension reported here was comparable to that
reported in phase III studies in various advanced solid tumours
treated with the VEGF inhibitor bevacizumab plus chemotherapy
(4–14.8%) (Sandler et al, 2006; Miller et al, 2007; Saltz et al, 2008).
These data favour the use of antihypertensive medication and
suggest the possible need for axitinib dose adjustments in patients
who develop hypertension while receiving axitinib plus
chemotherapy.
Of note, no cases of gradeX3 haemoptysis were reported in this
study, although mild haemoptysis was reported in one patient who
received axitinib plus paclitaxel/carboplatin. Bevacizumab is
contraindicated in patients with squamous cell NSCLC because
of the incidence of severe or fatal pulmonary haemorrhage (2004);
thus, patients with squamous cell NSCLC were excluded from the
phase III study evaluating bevacizumab combined with paclitaxel
and carboplatin for NSCLC (Sandler et al, 2006). In this study,
additional eligibility requirements, for example, exclusion of
patients who had blood vessels with possible tumour involvement,
may have mitigated, in part, the potential risk of haemoptysis. It
will require further investigation in a larger study to confirm
whether axitinib plus chemotherapy may be safely administered to
patients with squamous cell NSCLC. A phase II trial
(NCT00735904) evaluating axitinib combined with gemcitabine/
cisplatin for squamous cell NSCLC was recently completed.
Table 5 Plasma pharmacokinetic parameters of (A) paclitaxel, carboplatin, gemcitabine and cisplatin in the absence or presence of axitinib and (B) axitinib
in the absence or presence of paclitaxel, carboplatin, gemcitabine and cisplatin
Treatment arm
Mean (%CV)
(A) CT treatment with/without axitinib Cmax (ngml
 1) AUC0–N
a (ng .hml 1) CL (l h1) Vz(l) t½ (h)
Paclitaxelb,c (n¼ 12)
(þCarboplatin) 6182 (34) 20 266 (28) 21.6 (43) 285 (82) 8.36 (26)
(þCarboplatin)þ axitinib 7182 (24) 23 320 (34) 18.2 (24) 229 (31) 8.64 (12)
Carboplatinb,c (n¼ 12)
(þ Paclitaxel) 24 101 (29) 57 519 (17) 12.6 (32) 45.2 (18) 2.62 (21)
(þ Paclitaxel)þ axitinib 24 250 (32) 52 768 (15) 13.7 (31) 44.8 (15) 2.44 (29)
Gemcitabined (n¼ 17)
(þCisplatin) 22 445e (66) 11 680e (31) 224 (33) 91.5 (35) 0.29 (24)
(þCisplatin)þ axitinib 22 182 (34) 12 270 (33) 217 (36) 95.5 (63) 0.30 (33)
dFdU (þ cisplatin) 48 981 (39) 212 828 (39) – – 3.32 (44)
dFdU (þ cisplatin)þ axitinib 47 024 (17) 184 794 (20) – – 3.12 (16)
Cisplatinf (n¼ 13)
(þGemcitabine) 1899g (30) 3366g (25) 46.3 (32) 173 (53) 2.61 (49)
(þGemcitabine)þ axitinib 1757 (33) 3057 (30) 52.8 (44) 184 (96) 2.27 (77)
(B) Axitinib treatment with/without CT Cmax(ngml
 1) AUC0-24(ng .hml
 1) CL/F (l h1) Vz/F (l) t½ (h)
Axitinibh,i (n¼ 12)
Alone 39 (40) 404 (68) 39 (87) 108 (42) 2.8 (53)
þ Paclitaxel/carboplatin 46 (71) 535 (76) 37 (114) 133 (126) 2.7 (36)
Axitinibj (n¼ 20)
Alone 41 (81) 416 (108) 50.1 (113) 157 (102) 2.68 (41)
þGemcitabine/cisplatin 41.7 (94) 444 (84) 46.7 (104) 168 (116) 2.66 (51)
Abbreviations: AUC0–24¼ area under the plasma concentration–time curve (AUC) from time 0 to 24 h; AUC0–N¼AUC from time zero to infinity; b.i.d.¼ twice daily;
CL¼ plasma clearance; CL/F¼ apparent oral plasma clearance; Cmax¼maximum plasma concentration; CT¼ chemotherapy; CV¼ coefficient of variation; dFdU¼ 20 ,20-
difluorodeoxyuridine; PK¼ pharmacokinetic; PUF¼ plasma ultrafiltrate; t½¼ plasma terminal elimination half-life; Vz¼ volume of distribution of the drug during the elimination
phase; Vz/F¼ apparent oral volume of distribution during the elimination phase. aAUC reported for cisplatin is from time 0 to 8 h. bPooled data from cohorts 1–3. PK parameters
for carboplatin are in PUF. cTwo patients excluded because PK samples were not collected on cycle 1 day 1. dFour patients excluded because matching cycle 1 and cycle 2 PK
evaluations were not completed. eCmax and AUC0–N on cycle 2 dose-normalised for patients who underwent gemcitabine dose reduction on cycle 2 compared with cycle 1.
fSeven patients excluded because matching cycle 1 and cycle 2 PK evaluations were not completed; one patient excluded because of non-estimable half-life; one patient excluded
because of dose infusion interruption. PK parameters for cisplatin are in PUF. gCmax and AUC0–8 on cycle 2 dose-normalised for patients who underwent cisplatin dose reduction
on cycle 2 compared with cycle 1. hData were pooled from patients in cohorts 1, 2 and 3 who received 1, 3 and 5mg b.i.d. doses of axitinib, respectively. Data were dose-
normalised to 5mg b.i.d. iFor three patients, AUC0–24, CL/F, Vz/F and t1/2 were not reported because of non-estimable half-life.
jOne patient excluded because matching cycle 1
and cycle 2 PK evaluations were not completed; for five patients AUC0–24, CL/F, Vz/F, and t1/2 were not reported because of non-estimable half-life.
Axitinib plus platinum doublets for solid tumours
MF Kozloff et al
1282
British Journal of Cancer (2012) 107(8), 1277 – 1285 & 2012 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
Data reported here suggest the ability to administer paclitaxel/
carboplatin or gemcitabine/cisplatin with axitinib without altering
pharmacokinetics of these agents. Axitinib metabolism is primarily
mediated by CYP3A4 and to a lesser extent by CYP1A2, CYP2C19
and UDP-glucuronosyltransferase 1A1 as determined from in vitro
studies with human liver microsomes (unpublished data). In vitro
studies indicate that axitinib competitively inhibits CYP1A2 and
non-competitively inhibits CYP2C8 with inhibitor constants of
0.7mM (0.27 mgml–1) and 0.5 mM (0.19 mgml–1), respectively
(unpublished data). Since paclitaxel is an established CYP2C8
substrate (Monsarrat et al, 1993; Steed and Sawyer, 2007) and
axitinib inhibits CYP2C8 in vitro, increases in plasma concentra-
tions of paclitaxel when administered in combination with axitinib
were possible. Thus, patients were administered escalating lead-in
doses of axitinib (starting at 1mg b.i.d.) in sequential cohorts in
combination with paclitaxel/carboplatin. Similar paclitaxel phar-
macokinetics in the absence and presence of axitinib indicate that
at clinically relevant plasma concentrations of axitinib, significant
clinical CYP2C8 inhibition does not occur. In addition, there were
no clinically apparent exacerbations of known paclitaxel toxicities.
Similarly, no overt changes in pharmacokinetics were observed
between axitinib and cisplatin, carboplatin or gemcitabine and its
metabolite dFdU, although interactions were not anticipated since
axitinib is metabolised via pathways that are distinct from these
agents. Both carboplatin and cisplatin are eliminated by glomer-
ular filtration (Duffull and Robinson, 1997; Yao et al, 2007).
Gemcitabine (20,20-difluorodeoxycytidine) is sequentially phos-
phorylated intracellularly by deoxycytidine kinase and converted
to di- and triphosphate products. Observed plasma concentrations
of axitinib in combination with either paclitaxel/carboplatin or
gemcitabine/cisplatin were consistent with those reported in other
phase I studies of axitinib as monotherapy or in combination with
chemotherapy (Rugo et al, 2005; Sharma et al, 2010). Plasma
exposures observed in this study of paclitaxel, carboplatin (PUF),
cisplatin (PUF) and gemcitabine when administered alone were
similar to those previously reported in the literature (Villalona-
Calero et al, 2004; Kobayashi et al, 2007; Ricart et al, 2008;
Okamoto et al, 2010).
Combinations of bevacizumab with chemotherapy have shown
promising results in phase III studies of different tumour types;
however, randomised trials of tyrosine kinase inhibitors targeting
VEGF receptors in combination with chemotherapy have not
shown a benefit for these combinations. Although the efficacy data
for axitinib in combination with chemotherapy reported here are
encouraging, they are exploratory, as would be expected from any
phase I trial. The number of patients in each cohort was small,
making it difficult to draw any definitive conclusions about the
utility of axitinib combined with paclitaxel/carboplatin or gemci-
tabine/cisplatin in these patient populations. Nevertheless, they
offer direction for ongoing and future clinical studies with
sufficient statistical power for comprehensive analysis of the
safety and efficacy of these combinations for the treatment of
various cancers.
In conclusion, axitinib at a starting dose of 5mg b.i.d. may be
combined with paclitaxel/carboplatin or gemcitabine/cisplatin at
standard doses, with no apparent overlapping toxicities and no
overt changes in plasma pharmacokinetic parameters. Both
combinations showed antitumour activity in patients with
advanced solid tumours, including squamous cell NSCLC. Phase
II studies of axitinib in combination with paclitaxel/carboplatin,
gemcitabine/cisplatin and pemetrexed/cisplatin for NSCLC were
recently completed.
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Figure 3 Plasma concentration–time curves for (A) axitinib, paclitaxel and carboplatin and (B) axitinib, gemcitabine and cisplatin. Abbreviation:
PUF¼ plasma ultrafiltrate.
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